US FDA classification for Indore facility pending
Cipla awaits US FDA classification for its Indore facility, which was audited in February 2023. This could impact approvals for key products like generic Advair.
high · management_commentaryCipla Ltd — Q1 FY24
Cipla delivered a strong Q1 FY24 with 18% YoY revenue growth to INR 6,329 crore, driven by record performance in India (12% growth) and the US ($222 million, +43% YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Albuterol recall and market share loss
Cipla faced an Albuterol recall in Q1 and experienced a market share decline in Q4 FY23, though management states share has stabilized.
medium · management_commentaryPotential pricing pressure in US generics
While price erosion has eased, management noted it could revert to higher levels in later quarters, impacting US revenue sustainability.
medium · analyst_questionGoa facility re-inspection uncertainty
Cipla's Goa facility is under remediation and expects re-inspection in H2 FY24. Any adverse outcome could disrupt supply of key products.
high · management_commentary